Lack of benefit from nitric oxide synthase inhibition in patients with cardiogenic shock: Looking for the reasons

JAMA

Volumn 297, Issue 15, 2007, Pages 1711-1713

  Ndrepepa, Gjin ^a   Schömig, Albert ^a   Kastrati, Adnan ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

INOTROPIC AGENT; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ACUTE HEART INFARCTION; CARDIOGENIC SHOCK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BYPASS SURGERY; COUNTERPULSATION; DISEASE EXACERBATION; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG WITHDRAWAL; EDITORIAL; ENZYME INHIBITION; HEART ASSIST DEVICE; HEART MUSCLE REVASCULARIZATION; HEART OUTPUT; HUMAN; INCIDENCE; MORTALITY; MYOCARDIAL DISEASE; NONHUMAN; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 34247395721     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.15.1711     Document Type: Editorial

References (24)

1. Hochman JS, Sleeper LA, Webb JG, et al. SHOCK Investigators. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med. 1999;341:625-634.
2. Goldberg RJ, Gore JM, Thompson CA, Gurwitz JH. Recent magnitude of and temporal trends (1994-1997) in the incidence and hospital death rates of cardiogenic shock complicating acute myocardial infarction: the second National Registry of Myocardial Infarction. Am Heart J. 2001;141:65-72.
3. Babaev A, Frederick PD, Pasta DJ, Every N, Sichrovsky T, Hochman JS. NRMI Investigators. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA. 2005;294:448-454.
4. Goldberg RJ, Samad NA, Yarzebski J, Gurwitz J, Bigelow C, Gore JM. Temporal trends in cardiogenic shock complicating acute myocardial infarction. N Engl J Med. 1999;340:1162-1168.
5. Hochman JS, Sleeper LA, Webb JG, et al. SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating acute myocardial infarction. JAMA. 2006;295:2511-2515.
6. Chen EW, Canto JG, Parsons LS, et al. Investigators in the National Registry of Myocardial Infarction 2. Relation between hospital intra-aortic balloon counterpulsation volume and mortality in acute myocardial infarction complicated by cardiogenic shock. Circulation. 2003;108:951-957.
7. Hochman JS. Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation. 2003;107:2998-3002.
8. The TRIUMPH Investigators. Effect of tilarginine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial. JAMA. 2007;297:1657-1666.
9. Cotter G, Kaluski E, Blatt A, et al. L-NMMA (a nitric oxide synthase inhibitor) is effective in the treatment of cardiogenic shock. Circulation. 2000;101:1358-1361.
10. Cotter G, Kaluski E, Milo O, et al. LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J. 2003;24:1287-1295.
11. Alderton WK, Cooper CE, Knowles RG. Nitric oxide synthases: structure, function and inhibition. Biochem J. 2001;357:593-615.
12. MacNaul KL, Hutchinson NI. Differential expression of iNOS and cNOS mRNA in human vascular smooth muscle cells and endothelial cells under normal and inflammatory conditions. Biochem Biophys Res Commun. 1993;196:1330-1334.
13. Moncada S, Higgs EA. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J. 1995;9:1319-1330.
14. Smith TP Jr, Canty JM Jr. Modulation of coronary autoregulatory responses by nitric oxide: evidence for flow-dependent resistance adjustments in conscious dogs. Circ Res. 1993;73:232-240.
15. Radomski MW, Moncada S. Regulation of vascular homeostasis by nitric oxide. Thromb Haemost. 1993;70:36-41.
16. Grocott-Mason R, Anning P, Evans H, Lewis MJ, Shah AM. Modulation of left ventricular relaxation in isolated ejecting heart by endogenous nitric oxide. Am J Physiol. 1994;267:H1804-H1813.
17. Massion PB, Feron O, Dessy C, Balligand JL. Nitric oxide and cardiac function: ten years after, and continuing. Circ Res. 2003;93:388-398.
18. Wildhirt SM, Suzuki H, Horstman D, et al. Selective modulation of inducible nitric oxide synthase isozyme in myocardial infarction. Circulation. 1997;96:1616-1623.
19. Hannan RL, John MC, Kouretas PC, Hack BD, Matherne GP, Laubach VE. Deletion of endothelial nitric oxide synthase exacerbates myocardial stunning in an isolated mouse heart model. J Surg Res. 2000;93:127-132.
20. Caria C, Katz E, Scholz PM, Lazar MJ, Weiss HR. Myocardial stunning reduces the effects of nitric oxide on coronary capillary perfusion in the rabbit. Exp Physiol. 2002;87:335-342.
21. Vallance P, Moncada S. Role of endogenous nitric oxide in septic shock. New Horiz. 1993;1:77-86.
22. Dzavik V, Cotter G, Reynolds HR, et al; for the SHOCK-2 Investigators. Effect of nitric oxide synthase inhibition on hemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study. Eur Heart J. In press.
23. López A, Lorente JA, Steingrub J, et al. Multiple-center, randomized, placebocontrolled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
24. Seyfarth M, Fröhlich G, Sibbing D, et al. Left ventricular assist device (Impella LP 2.5) versus intraaortic balloon counterpulsation for patients with cardiogenic shock by myocardial infarction: a prospective, randomized trial (ISAR-SHOCK). Presented at: the Late-Breaking Emerging Technologies and Innovations Session of the 56th Annual Scientific Session of the American College of Cardiology; March 23, 2007; New Orleans, La.